30.01.2015 • NewsBASFCargillDede Willams

BASF Quits R&D Pact With Novozymes and Cargill

BASF has said it will exit its current R&D collaboration with Novozymes and Cargill to develop a bio-based process for producing 3-hydroxypropionic (3-HP) and acrylic acid from renewable raw materials.

The German chemical giant did not give a reason for leaving the partnership, but may be planning to continue working on the bio-acrylic acid separately. When joining the research it said it hoped to fast-forward its entry into the market for bio-based superabsorbent polymers used to make baby diapers, adhesive raw materials and coatings.

In September 2014, the group said it was "working full force" to set up a small integrated pilot plant by the end of the year.

The two US companies, which began working together in 2008 before being joined by BASF in 2008, are now looking for a new commercialization partner.

"This is pioneering biochemical research, and the technology development and achievements so far have been extraordinary," said Kristian Bjørneboe, Vice President for Business Creation and Acquisition at Novozymes.

The R&D cooperation has achieved its technical and business targets, the companies said. After demonstrating the production of 3-HP at pilot scale in 2013, the partners said a year later they had successfully converted the product to glacial acrylic acid and superabsorbent polymers and had selected this process for further scale-up.

In the petrochemical route, acrylic acid is produced by oxidation of propylene derived from the refining of crude oil.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.